SEC Form 4 · accession 0000914190-17-000318
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allan L Goldstein
Director
Period of report
Oct 19, 2017
Accepted (ET)
Oct 20, 2017 · 3:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 19, 2017 | C | 292,477 | $0.15 | A | 974,220 | D | |
| Common Stock | Oct 19, 2017 | X | 46,666 | $0.15 | A | 1,020,886 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory Note (right to buy)F1 | $0.15 | Oct 19, 2017 | C | 292,477 | D | Oct 19, 2012 | Oct 19, 2017 | Common Stock | 292,477 | 0 | D |
| Common Stock Warrant (right to buy) | $0.15 | Oct 19, 2017 | X | 46,666 | D | Apr 19, 2013 | Oct 19, 2017 | Common Stock | 46,666 | 0 | D |
Explanation of responses
- F1The Convertible Promissory Note in the principal amount of $35,000 accrued $8,871.60 in interest and both principal and interest were converted into 292,477 shares of common stock at a conversion price of $0.15 per share.